Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of conditions, such as Crohn’s disease (CD) and ulcerative colitis (UC). We are pursuing a comprehensive clinical trial program evaluating novel agents with the goal of advancing the care of patients suffering from UC and CD.